【摘要】 目的:前瞻性、非随机探索性研究,用定量冠状动脉(冠脉)造影方法(QCA),评价无聚合物微孔紫杉醇洗脱支架(YINYITMDES)置入冠脉原发(denovo)病变的近期、远期有效性和安全性。方法:2005-03至2005-09月大连医科大学附属第一医院和北京同仁医院的冠心病患者69例,年龄30～70岁,其中男性49例(71.0%),女性20例(29.0%),经冠脉造影(CAG)证实至少一支冠脉狭窄(冠脉原发病变,直径狭窄≥70%),靶病变长度≤26mm,靶血管直径2.5～3.5mm,按照常规方法行冠脉造影并置入YINYITMDES。结果:69例患者共放置79个支架。支架平均直径为(3.21±0.45)mm,置入支架长度平均为(18.29±6.09)mm。69例患者临床平均随访(11±2)个月,随访率100%。其中对45例患者(放置53个支架)在支架置入后9～13个月进行了冠脉造影随访,随访率65.2%。与术前相比,术后即刻最小内腔直径(MLD)明显改善,术前为(0.45±0.27)mm,支架术后为(3.21±0.45)mm,术后9～13个月与术后即刻相比,支架内再狭窄程度为(10.59±12.45)%,最小内腔直径(2.87±0.41)mm,支架内晚期管腔丢失(0.34±0.11)mm;支架内再狭窄率5.7%。结论:无聚合物微孔紫杉醇载药YINYITM对冠脉原发病变有较好的近期和远期治疗作用。更多还原

【Abstract】 Objective:To investigate the instant and long-term impact of YINYITM non-polymeric Paclitaxel drug eluting stent(DES)implantation on coronary artery de novo lesions by quantitative coronary angiography(QCA).Methods:We summarized 69 patients with coronary artery disease(CAD)from March to September 2005.Coronary angiography confirmed that at lest 1 vessel had de novo lesion with the stenosis≥70%,the length≤26 mm,and the target vessel diameter within 2.5-3.5 mm.The patients included 49 male(71%)and 20 female(29%),at the age of 30-70 years old.YINYITM non-polymeric Paclitaxel DES were launched on all lesions by percutaneous coronary intervention(PCI)and all patients were followedup for(11±2)months.Results:There were 79 YINYITM stents launched in all 69 patients.The average diameter of the stents was(3.21±0.45)mm and the length was(18.29±6.09)mm.45 patients with 53 stents received QCA examination from 9 to 13 months after PCI.The instant minimum lumen diameter(MLD)was improved from(0.45±0.27)mm pre-PCI to(3.21±0.45)mm post-PCI.During 9-13 months of time,QCA presented that the average MLD was(2.87±0.41)mm,and the late lumen loss was(0.34±0.11)mm.The total in-stent restenosis rate was 5.7%.Conclusion:YINYITM non-polymeric Paclitaxel DES implantation was beneficial in CAD patients with de novo coronary artery lesions for both instant and long term impact as confirmed by QCA.更多还原